secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apimeds Pharmaceuticals US, Inc. (APUS)
CIK:        0001894525
Form:       8-K/A
Filed at:   2026-04-09T23:59:59+00:00
Accession:  0001213900-26-042017
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apimeds: Majority stockholder consent to remove directors/officers is null and void
--------------------------------------------------------------------------------

- Inscobee Inc. and Apimeds, Inc. attempted written consent to remove directors Kogan, Koo, O’Donnell, Weintraub and officers Menon (CEO) and Frim (CFO).
- Company determined consent invalid due to violations of irrevocable proxy, consent waiver, and anti-frustration covenant in Support Agreement.
- Support Agreement expressly states any action taken in violation is null and void; consent void ab initio.
- Company will proceed with actions described in Schedule 14C Information Statement filed Feb 27, 2026, mailed March 5, 2026.
- This Amendment No. 1 clarifies the previously reported actions are of no force or effect.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894525/000121390026042017/0001213900-26-042017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894525/000121390026042017/ea0285032-8ka425_apimeds.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-042017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer